Jun 12, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA(TM) (tildrakizumab-asmn) in a Cross Section of People Living with Moderate-to-Severe Plaque Psoriasis
Jun 12, 2020
AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks
Apr 04, 2020
Analysis on Impact of COVID-19-Coal Tar Pitch Market Segmented by Application and Geographic Landscape 2019-2023 | Technavio
Jan 14, 2020
New Head-to-Head Phase 3 Data Show SKYRIZI(TM) (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks
Nov 21, 2019
Growth of Coal Tar Pitch Market to be Impacted by Increasing Use of Coal Tar Pitch in Roofing | Technavio
May 22, 2019
FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis
Feb 01, 2019
China Coal Tar Industry Report, 2019-2025: Upstream (Coal, Coke) and Downstream (Phenol Oil, Industrial Naphthalene, Coal Tar Pitch) - ResearchAndMarkets.com
Jan 06, 2019
Global Coal Tar Market 2019-2023| Key Insights| Technavio
Nov 01, 2018
Enstilar® is now covered by the Non-Insured Health Benefits Program for Adults with Psoriasis Vulgaris
Apr 09, 2018
Ortho Dermatologics Announces Publication Of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII(TM) In The Journal of the American Academy of Dermatology
Sep 05, 2017
Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118